Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TVM Capital Life Science is a prominent venture capital firm specializing in the life sciences sector. Founded in 1983 as a spin-off from Techno Venture Management, the firm has dedicated its efforts exclusively to life sciences since 2012. Headquartered in Munich, Germany, with an additional office in Montreal, Canada, TVM Capital Life Science has established a strong reputation for investing in innovative life science products. With assets under management totaling $900 million, the firm is well-positioned to support companies in becoming leaders within their respective market segments. TVM Capital Life Science's strategic partnership with Eli Lilly and Company enhances its investment capabilities, allowing the firm to leverage significant industry expertise and resources. This partnership is particularly beneficial for early-stage companies seeking to navigate the complexities of the life sciences landscape. The firm is known for its rigorous investment approach and commitment to addressing high unmet medical needs, making it a sought-after partner for startups in the biotech and healthcare sectors.
TVM Capital Life Science employs a dual-pronged investment strategy that focuses on both early-stage therapeutics and differentiated commercial-stage medical technologies. The firm primarily invests in innovative early-stage therapeutics through a single-asset company approach, which is bolstered by its strategic partnership with Eli Lilly and Company. This partnership allows TVM to provide substantial support to startups, particularly in the development of novel therapeutics. Additionally, the firm invests in commercial-stage medical technologies, diagnostics, digital health products, and late-stage therapeutics, targeting areas with high unmet medical needs such as oncology and immunology. TVM Capital Life Science is active across various investment stages, including pre-seed, seed, Series A, Series B, and Series C, enabling them to engage with companies at different points in their development. The firm seeks to partner with visionary founders who are committed to transforming healthcare through innovative solutions.
TVM Capital Life Science boasts a robust portfolio of successful investments in the life sciences sector. Notable companies include **Aurka Pharma Inc.**, which developed an aurora kinase A inhibitor and was acquired by Eli Lilly shortly after TVM's investment. Another significant investment was in **CoLucid Pharmaceuticals**, which focused on a novel migraine treatment and achieved a successful IPO before being acquired by Eli Lilly for $960 million. Additionally, **Acanthas Pharma, Inc.** developed a small molecule targeting mutations in multiple cancers and was also acquired by Eli Lilly. These successful exits highlight TVM Capital Life Science's ability to identify and nurture promising companies within the life sciences landscape, demonstrating their expertise and commitment to driving innovation in healthcare.
To pitch TVM Capital Life Science, please email info@tvm-capital.com. It is recommended to include a succinct overview of your business, highlighting the innovation and market potential. The firm is open to pitches from various stages, so ensure your proposal aligns with their focus on life sciences.
TVM Capital Life Science invests across multiple stages, including pre-seed, seed, Series A, Series B, and Series C. This broad investment range allows them to engage with companies at various points in their development.
Founders can pitch TVM Capital Life Science by sending an email to info@tvm-capital.com. It is advisable to provide a clear and concise overview of the business, including the problem being solved, the solution offered, and the market opportunity.
TVM Capital Life Science primarily focuses on the life sciences sector, with specific interests in biotech, healthcare, and digital health. They target innovative therapeutics and medical technologies that address high unmet medical needs.
The specific check sizes are not disclosed, but TVM Capital Life Science invests across various stages, which typically involves significant capital for early-stage and commercial-stage companies in the life sciences sector.
TVM Capital Life Science has a geographic focus on Europe and North America, allowing them to tap into diverse markets and innovative life science ecosystems.
While specific details on portfolio support are not provided, TVM Capital Life Science's strategic partnership with Eli Lilly suggests that they offer valuable insights and resources to help their portfolio companies succeed in the competitive life sciences landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.